Please login to the form below

Not currently logged in
Email:
Password:

Nurtec ODT

This page shows the latest Nurtec ODT news and features for those working in and with pharma, biotech and healthcare.

Pfizer to acquire Biohaven in deal worth over $11bn

Pfizer to acquire Biohaven in deal worth over $11bn

In addition to Nurtec ODT – known as Rimegepant and Vydura in the EU – the transaction involves the acquisition of Biohaven’s other calcitonin gene-related programmes. ... Medicine. “Nurtec ODT, which is already the number one prescribed migraine

Latest news

  • Pfizer snaps up Biohaven’s migraine drug for $1.24bn Pfizer snaps up Biohaven’s migraine drug for $1.24bn

    Neuroscience specialist Biohaven Pharmaceuticals has teamed up with Pfizer to commercialise its recently launched migraine drug Nurtec ODT (rimegepant) outside the United States. ... Nurtec ODT is currently under review by the European Medicines Agency

  • Biohaven gets FDA approval for migraine drug Nurtec ODT Biohaven gets FDA approval for migraine drug Nurtec ODT

    Biohaven Pharma has become the second drugmaker to bring an oral CGRP inhibitor to the US market for acute migraine, after the US Food and Drug Administration (FDA) approved its Nurtec ... Biohaven says Nurtec ODT (rimegepant) – its first commercial

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Madmicrobe Studios - Medical Animation

MadMicrobe is an award-winning team of certified medical illustrators creating animations that engage your audience with immersive experiences that bring...

Latest intelligence

The communication challenge of helping he next generation to be healthier
As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
Are we losing sight of what the democratisation of healthcare really looks like?
We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
William Kilgallon
How the Royal Society’s EiR programme can help to drive UK innovation
...